Foundayo vs Wegovy

Foundayo (orforglipron) and Wegovy (semaglutide 2.4 mg) are the most direct comparison you can make between an oral and an injected GLP-1 receptor agonist for chronic weight management. Both are FDA-approved for obesity, or overweight in adults with at least one weight-related comorbid condition, and both are taken as an adjunct to a reduced-calorie diet and increased physical activity. The differences come down to route of administration, magnitude of weight loss demonstrated in trials, cardiovascular evidence, and cost/coverage.

Both Are Approved for Chronic Weight Management

Foundayo was approved by the FDA on April 1, 2026. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI at least 30) or overweight (BMI at least 27) with at least one weight-related comorbid condition.

Wegovy has a very similar chronic-weight-management indication. Wegovy additionally has an FDA-approved indication to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight, based on the SELECT cardiovascular outcomes trial. Foundayo does not have a cardiovascular outcomes indication at the time of its initial approval.

Route of Administration

Foundayo is taken as a once-daily oral tablet, without food or water restrictions and at any time of day. It is the first GLP-1 receptor agonist to offer that level of oral flexibility.

Wegovy is a once-weekly subcutaneous injection, delivered via a prefilled pen into the abdomen, thigh, or upper arm.

For patients averse to injections, afraid of needles, or simply seeking oral convenience, Foundayo is the first realistic alternative for adults with obesity who want a modern GLP-1 without an injection. Previously, the only oral GLP-1 (Rybelsus) was approved only for type 2 diabetes, not weight loss, and required a 30-minute fasted water window.

Weight Loss Efficacy From Trials

The head-to-head trial data between orforglipron and semaglutide at the obesity dose is not yet available, so comparisons rest on separate placebo-controlled trials.

In ATTAIN-1 (72 weeks), orforglipron 36 mg produced approximately 12.4% body weight reduction versus about 0.9% with placebo. Approximately 59.6% of participants on the highest dose achieved at least 10% body weight reduction, and 39.6% achieved at least 15%.

In STEP 1 (68 weeks), semaglutide 2.4 mg produced approximately 14.9% body weight reduction versus about 2.4% with placebo, with roughly 86% achieving at least 5% loss and about 32% achieving at least 20%.

These are separate trials with different durations and populations; direct cross-trial comparison should be interpreted with caution. As a class-level pattern, injectable peptide semaglutide has shown numerically higher weight loss in its obesity trial than oral small-molecule orforglipron in its trial, but real-world outcomes depend on tolerability, adherence, and dose tolerance.

Cardiovascular and Condition-Specific Evidence

Wegovy has specific cardiovascular outcome data from SELECT, which supports its FDA cardiovascular indication. Wegovy is also FDA-approved for reduction of risk of serious heart problems in adults with obesity or overweight plus established cardiovascular disease.

Foundayo does not currently have cardiovascular outcome data supporting a CV indication. Orforglipron's cardiovascular outcomes trial program is ongoing but results have not been incorporated into the label at initial approval.

For patients with obesity and established cardiovascular disease, Wegovy has a clearer FDA-labeled benefit in that specific context.

Dosing Schedules

Foundayo is titrated from a low starting oral dose over several months with 4-week intervals between dose steps, up to the maintenance or maximum dose. Daily dosing is required for sustained effect.

Wegovy is titrated from 0.25 mg weekly to 2.4 mg weekly over approximately 16-20 weeks, with 4-week intervals between dose steps. Weekly dosing maintains the effect.

The tradeoff: a weekly injection is less frequent but requires an injection; a daily tablet avoids injections but requires consistent daily administration and can be affected by missed doses.

Side Effect Profiles Are Similar in Class

Both drugs produce the GLP-1 class side-effect pattern: nausea, vomiting, diarrhea, constipation, and dyspepsia, most often mild to moderate and reduced by slow titration. Both drugs carry a boxed warning regarding thyroid C-cell tumors based on rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.

In ATTAIN-1, the most common adverse events with orforglipron were gastrointestinal, with hair loss and fatigue also reported. In STEP 1 and other Wegovy trials, the most common adverse events were also gastrointestinal, and some patients experienced injection-site reactions, which would not apply to an oral tablet.

Both may increase risks of pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration from GI side effects.

Which Drug Fits Which Patient

• A patient seeking the oral convenience of a daily tablet without food or water restrictions may prefer Foundayo.
• A patient with established cardiovascular disease and obesity or overweight may benefit from Wegovy's FDA-labeled cardiovascular indication.
• A patient who has tried Wegovy and either wants to transition to an oral therapy or cannot tolerate the injection may consider Foundayo with their prescriber.
• A patient seeking maximum published weight loss in a trial should know that Wegovy's weight-loss data is numerically higher than Foundayo's in their respective trials, but tirzepatide (Zepbound) shows the largest weight-loss effect to date in trials.
• For comparisons between oral and injectable semaglutide, see our oral vs injectable GLP-1 overview.

Cost and Access Notes

Wegovy pricing has been established in the U.S. market for some time, with variable insurance coverage for obesity indications. Wegovy's cardiovascular indication has increased coverage in some plans when the patient has cardiovascular disease. Wegovy offers savings programs that make it accessible for commercially insured patients who qualify.

Foundayo pricing is being communicated at launch through LillyDirect. Insurance formulary decisions for Foundayo are still evolving as of mid-April 2026 and many commercial plans are expected to require prior authorization. Patients should confirm pricing, coverage, and copay obligations with their prescriber and insurer before filling.

This article is for informational purposes only and does not constitute medical advice. Prescribing decisions should be made between a patient and their healthcare provider based on the most current FDA labels, cardiovascular risk profile, preferences, and insurance coverage.